Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig) Treatment in Patients Who Did Not Tolerate Other 20% Subcutaneous Immunoglobulin Product(s)
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2020 Planned End Date changed from 10 Jul 2019 to 31 Aug 2021.
- 02 Mar 2020 Planned primary completion date changed from 10 Jul 2019 to 31 Aug 2021.
- 02 Mar 2020 Status changed from not yet recruiting to recruiting.